ArticleThe Pan African medical journal2025
Factors associated with severe adverse events following COVID-19 vaccine: a multicenter study in the Casablanca-Settat region of Morocco.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: in January 2021, a national COVID-19 vaccine campaign was launched in Morocco. The national pharmacovigilance system was strengthened to assess any adverse events related to the COVID-19 vaccine. The objective of this study was to analyse the factors associated with severe Adverse Events Following Immunization (AEFI) related to COVID-19 vaccines in the Casablanca-Settat region in Morocco. Methods: this multicentric, cross-sectional study was conducted among individuals who reported AEFI after COVID-19 vaccines. Factors associated with the occurrence of severe AEFI were analysed using logistic regression. Results: a total of 1257 reports (2538 AEFI) were analysed. The AstraZeneca vaccine was responsible for 65% of the AEFI. 74% of cases occurred after the first dose, and 92% were considered non-serious. Among the 95 serious cases, 51% presented their first AEFI within 24 hours of vaccination. Age ≥65 years (OR = 2.63; p < 0.001), male gender (OR = 1.75; p = 0.03), and a number of AEFI per patient ≥3 (OR = 2.08; p < 0.001) were associated with serious AEFI. Conclusion: although the majority of cases were non-serious, this study highlights the importance of vigilance, particularly for at-risk populations such as the elderly, men, and patients with a high number of AEFI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.